psoriasis

Graphic image of an arrow nailing the bullseye of a target
Biotech

Alumis beams as pivotal data on Sotyktu rival drive stock surge

Phase 3 psoriasis studies of Alumis’ TYK2 inhibitor hit their primary endpoints, setting the biotech up to file for approval of a Sotyktu challenger.
Nick Paul Taylor Jan 6, 2026 9:05am
Takeda

Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib

Dec 18, 2025 7:55am
crown royalty king queen win

J&J's IL-23 drug defeats Sotyktu in phase 3 psoriasis trial

Sep 17, 2025 9:45am
An arrow incrementally going up stairs before pointing straight up Blue background

Junshi sees ph. 3 psoriasis win for IL-17 drug, preps China push

Sep 8, 2025 4:54am
Shanghai China at sunrise

Fosun rises again, beaming up 3rd biotech deal in 3 weeks

Aug 29, 2025 10:05am
reshuffle pipeline target reorganize shift change

Lilly shakes up pain pipeline as part of quarterly R&D clearout

Aug 7, 2025 8:28am